Product Information
MOTEGRITY 2 MG TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $17.7512 per EA under NDC 54092054701. Its NADAC has been published 377 times since Jul 17, 2019.
FDA first approved this application on Dec 14, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the PRUCALOPRIDE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092054701
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PRUCALOPRIDE SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA210166FDA Approved
12/14/2018
TE Code
AB
On Market Since
12/14/2018
Pharmacological Classes
Price Statistics
The NADAC for MOTEGRITY 2 MG TABLET has been published 377 times since Jul 17, 2019, and over the history we have for it it has risen 29.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.7512 per EA |
|---|---|
| All-time high | $17.8240 (May 14, 2025) |
| All-time low | $13.6630 (Jul 17, 2019) |
| 52-week high | $17.8151 |
| 52-week low | $17.7500 |
| Median price | $16.1757 |
| Average price | $15.9497 |
| Largest weekly change | +6.0% (Jan 13, 2021) |
| Weeks tracked | 377 |
| Tracking since | Jul 17, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PRUCALOPRIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-4 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MOTEGRITY 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MOTEGRITY 2 MG TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $17.7512 per EA (NDC 54092054701), effective Sep 30, 2026.
How has the price of MOTEGRITY 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for MOTEGRITY 2 MG TABLET has risen 29.9%. It has been tracked across 377 weekly CMS publications since Jul 17, 2019.
What are the highest and lowest recorded NADAC prices for MOTEGRITY 2 MG TABLET?
Since Jul 17, 2019, the NADAC for MOTEGRITY 2 MG TABLET has ranged from a low of $13.6630 (Jul 17, 2019) to a high of $17.8240 (May 14, 2025), with a median of $16.1757 per EA.
Are there cheaper alternatives to MOTEGRITY 2 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PRUCALOPRIDE 2 MG TABLET, is $0.6190 per EA — about 97% below MOTEGRITY 2 MG TABLET.
Who manufactures MOTEGRITY 2 MG TABLET?
MOTEGRITY 2 MG TABLET (NDC 54092054701) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.